Bausch + Lomb Corporation (BLCO) has released an update.
Bausch + Lomb Corporation has announced FDA approval for its enVista Envy intraocular lens, designed to deliver a full range of vision with minimal disturbances. Clinical trials in the U.S. and Canada have shown high patient satisfaction and tolerance, with the product set to be available in the U.S. in a limited release soon and broadly in 2025.
For further insights into BLCO stock, check out TipRanks’ Stock Analysis page.
